Format

Send to

Choose Destination
Clin Exp Rheumatol. 2010 Sep-Oct;28(5):756-8. Epub 2010 Oct 22.

Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica.

Author information

1
Istituto Ortopedico Rizzoli, IRCCS, Bologna, Italy. lia.pulsatelli@ior.it.

Abstract

OBJECTIVES:

To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice.

METHODS:

Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA.

RESULTS:

No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse.

CONCLUSIONS:

PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

PMID:
20822713
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clinical and Experimental Rheumatology
Loading ...
Support Center